Pioneering Target Degrading Antibodies for Safer Cancer Therapies

At BioLoomics, we harness the vastness of protein design space using directed evolution in human cells.

Our Science

We Have a Unique Process To Discover Antibody Therapeutics That Traffic to Specific Subcellular Organelles
Learn More

Our Technology

We leverage activity-guided antibody library screening through Synthetic Biology, AI, Imaging, and Robotics to exponentially increase the rate of discovery of promising drug activity.
Learn More

About Us

Interdisciplinary pioneers driven by a common mission to create the next generation of antibody scaffolds.

We combine deep experience in synthetic biology, machine learning, and protein design to bring robust therapeutic solutions to patients with unmet needs.
Meet Our Team

Latest News

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

Sep 19, 2023

BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

Our mission is to make safer, more effective cancer therapeutics.

September 25, 2023
View News Article

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

Sep 19, 2023

Backed by former Google CEO’s VC, a Colorado biotech hatches platform to evolve degraders

BioLoomics’ goal is to make a degrader from an antibody in one month

September 26, 2023
View News Article

Pre-Seed Extension

May 11, 2021

Pre-Seed Extension

BioLoomics closed a $575,000 round of pre seed extension funding on May 11, 2021..

September 25, 2023
View News Article

OEDIT Grant Award

Nov 21, 2019

OEDIT Grant Award

The Colorado OEDIT provides funding opportunities to small businesses in fourteen industries...

September 26, 2023
View News Article

BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform

May 30, 2019

BioLoomics Closes $600k Pre-Seed Round to Launch Biosensing Drug Discovery Platform

We are excited to announce that on May 30, 2019, BioLoomics closed a $600,000 pre-seed round...

September 25, 2023
View News Article
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.